| INTRODUC TI ON
Endometrial cancer (EC) is the most common gynecological malignancy and its incidence is increasing. 1 Although a great majority of patients with uterine-limited EC (stage I, II) generally show a favorable prognosis, those with stage III and IV disease show poor prognosis with five-year survival of approximately 82.9% and 26.7%, respectively. 1 Factors affecting the prognosis include type 2 histological subtypes, increased depth of myometrial invasion, and lymph node metastasis. 2 To improve the prognosis, early detection and diagnosis of cancerous and precancerous lesions are of great importance. Transvaginal ultrasound is a non-invasive method to screen tumors in the uterine, fallopian tube, and ovary, but it is difficult to detect tumors at a very early stage and discriminate malignant tumors from non-malignant changes. Although endometrial hysteroscopy and/or curettage may be used for the diagnosis, this intervention is difficult to apply for screening because it is invasive, time-consuming, and expensive. Endometrial cytology by brush sampling has been widely applied for the screening of endometrial neoplasms. 3 This method is a simple, painless, inexpensive and relatively accurate strategy to obtain materials for cancer detection, showing a sensitivity of 79% and a specificity of 99%. 4 However, there are some factors that interfere with conventional smear quality, and the presence of excess blood is one of the main factors. 5 Therefore, standardization of cytological diagnostic criteria and appropriate handling of samples are problems to be improved for the augmentation of its sensitivity. [6] [7] [8] Liquid-based cytology (LBC) has increased the sensitivity up to 100% for postmenopausal subjects, but the sensitivity remains at approximately 53% for premenopausal women. 9 LBC has a great advantage in cell preservation and clearance of background, both of which are crucial for accurate diagnoses. 5 Although LBC is useful for precise observation of cell components in the endometrial samples, evaluation of glandular architecture relies indirectly on the morphology of cell clumps. Therefore, LBC alone is insufficient for the detection of early EC, and the development of new diagnostic approaches is a matter of concern.
Next generation sequencing (NGS) has increased the sensitivity of detection of somatic mutations. NGS has also enabled the detection of somatic mutations at low frequencies in cancer tissues, and the identification of tumor DNA derived from cancer tissues (ctDNA) in circulating peripheral blood. (n = 2), cervical cancer (n = 2), ovarian cancer (n = 2), benign gynecological diseases (n = 21), and women without involvement of gynecological organs (n = 3) ( Table 1 ). Benign gynecological diseases comprised myoma uteri (n = 12), adenomyosis (n = 2), CIN cervical intraepithelial neoplasia (n = 2), and lobular endocervical glandular hyperplasia (n = 2), endometrial hyperplasia (n = 2), and benign ovarian tumor (n = 1).
| MATERIAL S AND ME THODS

| Patients and their clinical information
| Sampling and cytological examination
For endometrial LBC, Scree brush (Soft Medical Co., Ltd, Tokyo, Japan) was gently inserted to the level of the uterine fundus.
The outer sheath was then pulled back, and the brush was rotated in the uterine cavity. Then the outer sheath was pushed in again, and the brush was removed. The sample was placed into 10 mL of LBC Prep liquid (Muto Pure Chemicals Co., Ltd, Tokyo, Japan), and 8 mL of the liquid was used for cytological diagnosis and the remaining 2 mL was used for genetic analysis.
Cytological diagnosis was carried out and evaluated according 
| Extraction of DNA and PCR
DNA was extracted from the 2 mL of the LBC sample using a QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations, and the amount of DNA was subsequently quantified using NanoDrop (Thermo Fisher Scientific K.K., Tokyo, Japan). Regions including mutation hot spots in PTEN, PIK3CA, CTNNB1, KRAS, and TP53 were amplified using gene-specific primer sets (Table S1 ). DNA (25 ng) was mixed with 10 pmol of forward and reverse primers in a reaction mixture of 25 μL containing five units of KOD plus NEO Taq polymerase (TOYOBO, Osaka, Japan).
All reactions involved initial denaturation at 95°C for 2 minutes followed by 35 cycles at 98°C for 30 seconds, 60°C for 30 s, and 68°C for 30 seconds, and final extension at 68°C for 5 minutes on a Veriti Thermal Cycler (Thermo Fisher Scientific, Waltham, MA, USA). The PCR products were quantified using LabChip GX Touch (PerkinElmer, Waltham, MA, USA).
| Sequencing and analysis of data
Amplicon sequencing was carried out using MiSeq platforms with paired-end reads of 101 bp according to the manufacturer's instructions (Illumina, San Diego, CA, USA). Sequence libraries were prepared using 1 μg of a mixture of PCR products from the same sample and barcodes. For data processing, fastq files were aligned to human reference sequence (hg19) and bam files were created using MiSeq
Reporter (Illumina). Variants were determined by comparison of the bam files with the reference sequence using MiSeq Reporter.
| RE SULTS
| Cytological diagnosis
Cytological assessment of the 48 LBC showed that 16 samples were "positive or suspicious for malignancy" and the remaining 32 were Table S2 . Thirteen of the 18 endometrioid carcinomas were at early stages (Ia and Ib) of grade 1-2. In the remaining 26 cases, no uterine neoplasms were identified by cytology or transvaginal ultrasound. Among the 20 EC, 15 were "positive or suspicious for malignancy" (Table S2) indicating that the sensitivity of cytology alone was 75%. The remaining five cases were all stage I cases that were diagnosed by transvaginal ultrasound and curettage/ biopsy analysis, although they were negative for malignancy by LBC.
The five false-negative cases included three of seven premenopausal EC patients and two of 13 postmenopausal patients (Table S2 ). This data may imply a tendency for decreased sensitivity for cytological EC diagnosis in premenopausal patients than postmenopausal patients, although a significant difference was not observed. The two carcinosarcomas were correctly diagnosed as "positive or suspicious for malignancy" by LBC. Only one of the two cervical adenocarcinomas was identified as positive by the cytology. These data suggest that there is a limit for the early detection of EC by LBC alone. six PIK3CA variants in nine, three CTNNB1 variants in five, two KRAS variants in four, and three TP53 variants in three (Table 2) .
| Detection of variants in the five genes
Regarding the PTEN mutations in the LBC samples, the allele frequencies of each mutation ranged from 8% to 56% with an average of 31.1%, suggesting a high proportion of tumor cells in the LBC samples. Although the average frequencies of pathogenic mutations in PIK3CA, CTNNB1, and TP53, were 32.1%, 25.8%, and 44.7%, respectively, the frequency of KRAS mutation ranged from 8% to 9%
with an average of 8.5%. Notably, in LB-176, the frequency of KRAS mutation was 8% but the frequencies of two PTEN mutations were 24% and 26%. These data suggest that the difference in mutation frequencies may reflect intratumor heterogeneity of EC, and that KRAS mutation(s) may be acquired after the accumulation of trunk mutation(s) in the PI3K-AKT and/or other pathways. Regarding PIK3CA, we identified a total of six variants in nine women.
| Analysis of variations
Five of the six were nonsynonymous variants and were categorized as pathogenic mutations, but the remaining one was a synonymous single nucleotide polymorphism (rs17849079) and was regarded as a non-pathogenic variant in the COSMIC database. Mutations of CTNNB1, KRAS, and TP53 were found in five, four, and three cases, respectively, and all were regarded as pathogenic mutations. Taken together, 19 of the 48 subjects carried at least one pathogenic variant in the five genes (Figure 1 ).
| Association of mutations with clinical information
Among the 19 subjects with at least one pathogenic mutation, 15
were diagnosed as endometrioid carcinoma, two as endometrial carcinosarcoma, and one as cervical adenocarcinoma. Although the remaining case carried a KRAS mutation, no cytological or ultrasound abnormalities were identified in the patient who suffered from familial adenomatous (FAP) polyposis of the colon. In the 15 endometrioid carcinoma cases, 11 patients were at stage I ( Figure 2 , Table S2 ), implying that LBGDx can detect endometrioid cancer at early stages. It is of note that three of the 20 EC had no pathogenic mutation in the five genes, suggesting that screening of the five genes or hot spot regions may not be sufficient to identify all EC cases.
| Comparison between LBC with LBGDx
Liquid-based cytology correctly diagnosed 15 of the 20 EC (nine malignant and six suspicious cases) but failed to identify five early endometrial cancers (75% sensitivity) (Figure 2 , Table S2 ). All 16 
| D ISCUSS I ON
In the present study, we identified frequent mutations in PTEN in EC by amplicon sequencing of the five genes and showed that LBGDx contributes to enhanced sensitivity of cytological screening for endometrial cancer. Although the number of samples analyzed in this study is limited, the frequencies of mutations in the five genes are in good agreement with previous reports. 13, 14 It is of note that frequent mutations of TP53 have been found in aggressive endometrial carcinomas including high-grade serous types and carcinosarcomas. 15 In addition, TP53 (75.5%) and PIK3CA (34.0%) mutations are most frequently observed in uterine carcinosarcoma. 16 Consistent with these reports, we identified TP53 mutations in the two patients with carcinosarcomas and in a patient with endometrioid carcinoma at stage IIIc2. Additionally, PIK3CA and KRAS mutations were identified in one of the two cases with cervical adenocarcinoma.
Kinde et al reported that DNA extracted from liquid uterine specimen is useful for the diagnosis of EC and ovarian cancer. CTNNB1, and 44.7% vs 23% for TP53). 11 Although the frequencies of mutant alleles were less than ours, they identified at least one somatic mutation in all 12 EC patients. As they analyzed a greater number of genes than in our study (12 genes vs 5 genes), the increase of the target genes and/or regions for amplicon sequencing could have augmented the sensitivity.
The same group recently published the results of a larger study including 382 patients with EC, 245 with ovarian cancer, and 714 control women without cancer. 12 They applied Pap brush samples for panel sequencing of 18 genes. They detected somatic mutations in 81% of patients with EC, and the median of mutated allele frequency was 0.54%. Furthermore, they carried out the same panel sequencing with samples using a Tao brush for endometrial cytology from 123 patients with EC, 51 with ovarian cancers, and 125 control women without cancer. Consequently, they identified at least one driver gene mutation in 93% of samples from EC patients, and the median of mutant allele frequency was 24.7%, which was much higher than the Pap brush samples. Our data are comparable with theirs, as we identified pathogenic mutations in 85% of EC in LBC samples by amplicon sequencing of five genes, and the median of mutant allele frequencies in the five genes was 26%.
Maritschnegg et al also determined tumor-specific mutations using cells that were collected through a lavage of the uterine cavity. 17 Germline mutations in PTEN are responsible for Cowden syndrome. In the present study, we found 11 PTEN variants at a frequency ranging from 8% to 56%, and five cases showed more than 40%. Therefore, it is difficult to discriminate somatic mutations from germline variants in the five cases. However, Cowden syndrome is a rare autosomal dominant disorder and the frequency of this disease is considered to be approximately one in 200 000 individuals. 22 In addition, no abnormality was found in 240 patients with endometrial cancer in the screening of PTEN mutations. 23 Therefore, we assumed that the PTEN variants were somatic mutations.
We have shown herein that LBGDx could diagnose EC at a sensitivity of 85%. Among 17 EC cases diagnosed by LBGDx, five cases were negative for cytological diagnosis, corroborating that it is difficult to diagnose EC by cytology alone. 
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